


**AMENDMENTS TO THE CLAIMS**


Please amend the following claims:

1. (currently amended): A compound of the general formula (I)



or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

D is a heterocyclic ring selected from:



where  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$  are optionally substituted carbon, or one of  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$  is nitrogen and the rest optionally substituted carbon;

$R_2$  is 0-3 substituents independently chosen from H, halogen,  $C_{1-4}$  alkyl,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , CN, aryl, hetaryl,  $C_{1-4}$  alkylOH,  $C_{1-4}$ alkylNR $_3$ R $_4$ ,  $C_{1-4}$ alkylhetaryl,  $OC_{1-4}$  alkyl,  $OC_{1-4}$ alkylNR $_3$ R $_4$ ,  $OC_{1-4}$ alkylhetaryl,  $OC_{1-4}$  alkylOH,  $CO_2R_3$ , CONR $_3$ R $_4$ , NR $_3$ R $_4$ , nitro, NR $_3$ COR $_4$ , NR $_5$ CONR $_3$ R $_4$ , NR $_3$ SO $_2$ R $_4$ ,  $C_{1-4}$ alkylNR $_3$ COR $_4$ ,  $C_{1-4}$ alkylNR $_5$ CONR $_3$ R $_4$ ,  $C_{1-4}$ alkylNR $_3$ SO $_2$ R $_4$ ;

$R_3$ ,  $R_4$  are each independently H,  $C_{1-4}$  alkyl,  $C_{1-4}$ alkylOH,  $C_{1-4}$ alkylNR $_1$ R $_2$ ,  $C_{1-4}$  alkyl cycloalkyl,  $C_{1-4}$  cyclohetalkyl, aryl,  $C_{1-4}$  alkylaryl, hetaryl,  $C_{1-4}$  alkylhetaryl, or may be joined to form an optionally substituted 3-8 membered (saturated or unsaturated) ring optionally containing an atom selected from O, S, NR $_6$ ;

and  $R_5$  is selected from H,  $C_{1-4}$  alkyl, aryl or hetaryl;

$R_6$  is selected from H,  $C_{1-4}$  alkyl,  $C_{1-4}$ alkylNR $_1$ R $_2$ , aryl, hetaryl,  $C_{1-4}$  alkyl aryl,  $C_{1-4}$  alkyl hetaryl;

$R_{19}$ ,  $R_{20}$  are each independently selected from H,  $C_{1-4}$ alkyl;

R1 is H, C<sub>1-4</sub> alkyl, C<sub>1-6</sub> cycloalkyl, or may form a 5-8 membered ring onto the ortho position of ring A;

Q is a bond, [~~CH<sub>2</sub>-C<sub>1-4</sub> alkyl~~], CH, C<sub>1-4</sub> alkylene;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, CN, NR<sub>8</sub>R<sub>9</sub>, aryl, hetaryl, C<sub>1-4</sub>aryl, C<sub>1-4</sub>hetaryl, C<sub>1-4</sub> alkylNR<sub>8</sub>R<sub>9</sub>, OC<sub>1-4</sub> alkylNR<sub>8</sub>R<sub>9</sub>, nitro, NR<sub>10</sub>C<sub>1-4</sub>NR<sub>8</sub>R<sub>9</sub>, NR<sub>8</sub>COR<sub>9</sub>, NR<sub>10</sub>CONR<sub>8</sub>R<sub>9</sub>, NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, CONR<sub>8</sub>R<sub>9</sub>, CO<sub>2</sub>R<sub>8</sub>;

R<sub>8</sub> and R<sub>9</sub> are each independently H, C<sub>1-4</sub> alkyl, aryl or together form an optionally substituted 4-8 membered ring which may contain a heteroatom selected from O, S, NR<sub>11</sub>;

R<sub>10</sub> is selected from H, C<sub>1-4</sub> alkyl;

R<sub>11</sub> is selected from H, C<sub>1-4</sub> alkyl;

W is selected from H, C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl or may form a 5-8 membered ring onto the ortho position of ring A; where C<sub>1-4</sub>alkyl or C<sub>2-6</sub>alkenyl may be optionally substituted with C<sub>1-4</sub>alkyl, OH, OC<sub>1-4</sub>alkyl, NR<sub>12</sub>R<sub>13</sub>;


R<sub>12</sub>, and R<sub>13</sub> are each independently H, C<sub>1-4</sub>alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR<sub>14</sub>;

R<sub>14</sub> is selected from H, C<sub>1-4</sub> alkyl;

Y is 0-2 substituents selected from H, C<sub>1-4</sub> alkyl, NR<sub>15</sub>R<sub>16</sub>;


R<sub>15</sub> and R<sub>16</sub> are independently selected from H, C<sub>1-4</sub>alkyl.

2. (original): A compound according to formula (I) of claim 1, wherein the compound is selected from compounds of the general formula (II):



or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

D is a heterocyclic ring selected from:



where  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$  are optionally substituted carbon, or one of  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$  is N and the rest optionally substituted carbon;

$R_2$  is 0-3 substituents independently chosen from H, halogen,  $C_{1-4}$  alkyl,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , CN, aryl, hetaryl,  $C_{1-4}$  alkylOH,  $C_{1-4}alkylNR_3R_4$ ,  $C_{1-4}alkylhetaryl$ ,  $OC_{1-4}alkyl$ ,  $OC_{1-4}alkylNR_3R_4$ ,  $OC_{1-4}alkylhetaryl$ ,  $OC_{1-4}alkylOH$ ,  $CO_2R_3$ ,  $CONR_3R_4$ ,  $NR_3R_4$ , nitro,  $NR_3COR_4$ ,  $NR_5CONR_3R_4$ ,  $NR_3SO_2R_4$ ,  $C_{1-4}alkylNR_3COR_4$ ,  $C_{1-4}alkylNR_5CONR_3R_4$ ,  $C_{1-4}alkylNR_3SO_2R_4$ ;

$R_3$ ,  $R_4$  are each independently H,  $C_{1-4}$  alkyl,  $C_{1-4}alkylOH$ ,  $C_{1-4}alkylNR_{19}R_{20}$ ,  $C_{1-4}alkyl$  cycloalkyl,  $C_{1-4}cyclohetalkyl$ , aryl,  $C_{1-4}alkylaryl$ , hetaryl,  $C_{1-4}alkylhetaryl$ , or may be joined to form an optionally substituted 3-8 membered (saturated or unsaturated) ring optionally containing an atom selected from O, S,  $NR_6$ ;

and  $R_5$  is selected from H,  $C_{1-4}$  alkyl, aryl or hetaryl;

$R_6$  is selected from H,  $C_{1-4}$  alkyl,  $C_{1-4}alkylNR_{19}R_{20}$ , aryl, hetaryl,  $C_{1-4}alkylaryl$ ,  $C_{1-4}alkylhetaryl$ ;

$R_{19}$ ,  $R_{20}$  are each independently selected from H,  $C_{1-4}alkyl$ ;

$R_1$  is H,  $C_{1-4}$  alkyl,  $C_{1-6}$  cycloalkyl, or may form a 5-8 membered ring onto the ortho position of ring A;

A is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen,  $C_{1-4}$  alkyl,  $CF_3$ ,  $OCF_3$ , CN,  $NR_8R_9$ , aryl, hetaryl,  $C_{1-4}aryl$ ,  $C_{1-4}hetaryl$ ,  $C_{1-4}alkylNR_8R_9$ ,  $OC_{1-4}alkylNR_8R_9$ , nitro,  $NR_{10}C_{1-4}NR_8R_9$ ,  $NR_8COR_9$ ,  $NR_{10}CONR_8R_9$ ,  $NR_8SO_2R_9$ ,  $CONR_8R_9$ ,  $CO_2R_8$ ;

$R_8$  and  $R_9$  are each independently H,  $C_{1-4}$  alkyl, aryl or together form an optionally substituted 4-8 membered ring which may contain a heteroatom selected from O, S,  $NR_{11}$ ;

$R_{10}$  is selected from H,  $C_{1-4}alkyl$ ;

$R_{11}$  is selected from H,  $C_{1-4}alkyl$ ;

W is selected from H, C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl or may form a 5-8 membered ring onto the ortho position of ring A; where C<sub>1-4</sub>alkyl or C<sub>2-6</sub>alkenyl may be optionally substituted with C<sub>1-4</sub>alkyl, OH, OC<sub>1-4</sub>alkyl, NR<sub>12</sub>R<sub>13</sub>;


R12, and R13 are each independently H, C<sub>1-4</sub>alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR14;


R14 is selected from H, C<sub>1-4</sub> alkyl;

Y is 0-2 substituents selected from H, C<sub>1-4</sub> alkyl, NR<sub>15</sub>R<sub>16</sub>;


R15 and R16 are independently selected from H, C<sub>1-4</sub>alkyl.

3. (currently amended): A compound ~~[[according to formula (I) of claim 1]]~~ selected from the group consisting of:







1





1





1



1




1






1













1

















1














1




1




1




1




1




1




1





1




1




1



1





4. (original): A compound according to formula (I) of claim 1 selected from the group consisting of

6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine,  
6-(1H-Benzimidazol-1-yl)-N-[(1R)-1-phenylethyl]pyrazin-2-amine,  
6-(1H-Benzimidazol-1-yl)-N-[(1S)-1-phenylethyl]pyrazin-2-amine,  
1-(6-{[1-(3-Fluorophenyl)ethyl]amino}pyrazin-2-yl)-1H-benzimidazole-5-carboxamide,  
1-(6-{[1-(3-Fluorophenyl)ethyl]amino}pyrazin-2-yl)-1H-benzimidazole-6-carboxamide,  
1-(6-{[1-(3-Fluorophenyl)ethyl]amino}pyrazin-2-yl)-1H-benzimidazole-6-carbonitrile,  
1-[6-(3,4-Dihydroisoquinolin-2(1H)-yl)pyrazin-2-yl]-1H-benzimidazole-5-carbonitrile,  
1-[6-(3,4-Dihydroisoquinolin-2(1H)-yl)pyrazin-2-yl]-1H-benzimidazole-6-carbonitrile,  
1-{6-[(1S)-1,2,3,4-Tetrahydronaphthalen-1-ylamino]pyrazin-2-yl}-1H-benzimidazole-5-carbonitrile,

1-{6-[(1S)-1,2,3,4-Tetrahydronaphthalen-1-ylamino]pyrazin-2-yl}-1H-benzimidazole-6-carbonitrile,

1-(6-{[(1S)-1-Phenylethyl]amino}pyrazin-2-yl)-1H-benzimidazol-5-amine,

1-(6-{[(1S)-1-Phenylethyl]amino}pyrazin-2-yl)-1H-benzimidazol-6-amine,

N-[1-(6-{[(1S)-1-Phenylethyl]amino}pyrazin-2-yl)-1H-benzimidazol-6-yl]-2,2-dimethylpropanamide,

N-[1-(6-{[(1S)-1-Phenylethyl]amino}pyrazin-2-yl)-1H-benzimidazol-5-yl]acetamide,

N-[1-(6-{[(1S)-1-Phenylethyl]amino}pyrazin-2-yl)-1H-benzimidazol-5-yl]methanesulfonamide,

2-(S- $\alpha$ -Methylbenzylamino)-6-(5-(N-methylpiperazin-4-yl-methyl)-benzimidazo-1-yl)-pyrazine,


[1-(6-{[1-(4-Fluorophenyl)ethyl]amino}pyrazin-2-yl)-1H-benzimidazol-5-yl]methanol,

[1-(6-{[1-(4-Fluorophenyl)ethyl]amino}pyrazin-2-yl)-1H-benzimidazol-6-yl]methanol,


and

N-[1-(4-Fluorophenyl)ethyl]-6-{6-[(4-methylpiperazin-1-yl)methyl]-1H-benzimidazol-1-yl}pyrazin-2-amine.

5. (currently amended): The compound of claim 3, wherein said compound is:



or



or a pharmaceutically acceptable prodrug, salt, hydrate, solvate, crystal form or diastereomer thereof.

6. (canceled)

7. (currently amended): A composition comprising a carrier and at least one compound according to claim 3 [~~any one of claims 1 to 6~~].

8. (currently amended): A method of treating a tyrosine kinase-associated disease state in a subject, the method comprising administering a therapeutically effective amount of a

compound according to claim 3 or a pharmaceutical composition thereof ~~[[any one of claims 1 to 6 or a composition according to claim 7]]~~.

9. (original): A method of treating a kinase-associated disease state according to claim 8, wherein the disease state involves JAK1, JAK2, JAK3 or TYK2.

10. (currently amended): A method according to claim ~~[[8 or]]~~ 9 wherein the disease state is selected from the group consisting of Atopy, Cell Mediated Hypersensitivity, Rheumatic Diseases, Other autoimmune diseases, Viral Diseases, Cancer, Neurodegenerative Diseases, and Cardiovascular Diseases.

11. (canceled)

12. (currently amended): A method of treating diseases and conditions associated with inflammation and infection in a subject, the method comprising administering a therapeutically effective amount of at least one compound according to claim 3 or a pharmaceutical composition thereof ~~[[any one of claims 1 to 6 or a composition according to claim 7]]~~.

13. (new): The compound of claim 1, wherein Y is 1-2 substituents.


14. (new): The compound of claim 1, wherein Y is 0 and R2 is OCHF<sub>2</sub>, CN, C<sub>1-4</sub> alkylOH, C<sub>1-4</sub>alkylhetaryl, OC<sub>1-4</sub> alkyl, OC<sub>1-4</sub>alkylNR<sub>3</sub>R<sub>4</sub>, OC<sub>1-4</sub>alkylhetaryl, or OC<sub>1-4</sub> alkylOH.

15. (new): The compound of claim 1, wherein R2 is CN.


16. (new): The compound of claim 1, wherein R1 forms a 5-8 membered ring onto the ortho position of ring A.

17. (new): The compound of claim 16, wherein Q is CH and W is H.

18. (new): A compound having the formula



or



wherein A is phenyl;

n is 0 or 1;

R is H, OCH<sub>3</sub> or halo; and

R<sup>1</sup> is H or CH<sub>3</sub>.